Pmv Pharmaceuticals (PMVP) news
Recent news
PMV Pharmaceuticals, - Plans NDA submission for accelerated approval of Rezatopopt in Q1 2027
AInvest Wire · Oct 5, 2026PMV Pharmaceuticals appoints Philip Herman as chief commercial officer
AInvest Wire · Sep 8, 2026PMV Pharma announces proposed public offering of securities
AInvest Wire · Aug 31, 2026PMV Pharmaceuticals, - Rezatopopt shows favorable safety profile with 5% discontinuation rate due to adverse events
PMV Pharmaceuticals recently reported preliminary safety data from its ongoing clinical trials of Rezatopopt, indicating a favorable safety profile. According to the data, only 5% of participants discontinued treatment due to adverse events, a figure that is within the range typically observed for…
AInvest Wire · Aug 31, 2026PMV Pharmaceuticals, - Median time to response 1.3 months, median duration of response 10.0 months
PMV Pharmaceuticals recently reported clinical trial results for its investigational therapy, indicating a median time to response of 1.3 months and a median duration of response of 10.0 months [1]. These findings are part of an ongoing evaluation of the drug candidate's efficacy and safety profile…
AInvest Wire · Aug 31, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.